Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0622O)

Drug Name
Nipocalimab Drug Info
Indication
Disease Entry ICD 11 Status REF
Myasthenia gravis 8C6Y Phase 3 [1]
Rheumatoid arthritis FA20 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DM0622O

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Immunoglobulin Fc receptor (FCR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Rozanolixizumab DMK0NGB Generalized myasthenia gravis 8C60 Approved [4]
DX-2500 DM3BWTM Ischemic heart disease BA40-BA6Z Investigative [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Immunoglobulin Fc receptor (FCR) TTPY4SE NOUNIPROTAC Antagonist [3]

References

1 ClinicalTrials.gov (NCT04951622) Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04991753) A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept Study Evaluating the Efficacy and Safety of Nipocalimab Administered Intravenously in Participants With Active Rheumatoid Arthritis Despite Standard Therapy. U.S.National Institutes of Health.
3 Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals. Drugs. 2022 Jun;82(8):865-887.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates. Front Immunol. 2015; 6: 176.